All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Acute graft-versus-host disease (aGvHD), as defined by the Mount Sinai Acute GvHD International Consortium (MAGIC) of the European Society for Blood and Marrow Transplantation (EBMT), is a serious complication of hematopoietic stem cell transplantation (HSCT).3 To date, corticosteroids are the accepted first-line treatment. However, in many patients steroid resistance or steroid dependence may develop.
On Saturday 18 May 2019, at the 1st EBMT GvHD Summit, Warsaw, PL, Olaf Penack from Charité, Berlin, DE, presented an educational talk about the recommendations of the EBMT– European Leukemia Net (ELN) consensus working group regarding the treatment of aGvHD.
The recommendations were produced by a task force of 5 experts and build on consensus statements from 20 EBMT and ELN working group members as well as other transplant experts in the field. GvHD Hub steering committee members Mohamed Mohty, Robert Zeiser, Hildegard Greinix, Arnon Nagler and Grezegorz Basak, were part of the working group. The recommendations were based on the current standard of practice throughout European hematology centers, utilizing a Delphi-like approach (≤ 80% approval of a method led to consensus).
The working group is dedicated to improve compliance with the EBMT–ELN recommendations in everyday clinical practice, in order to reduce heterogeneity in GvHD management and support optimal procedures. The end goal is to further improve the outcomes of allogeneic transplantations throughout Europe.
Olaf Penack concluded by stating that a “high level of consensus (≥95%) was reached in all statements as well as a good basis of these implementations was given”. Based on a follow up survey after release of the latest guidelines, Doctor Penack stated that he is expecting difficulties regarding the standardized clinical implementation.
Your opinion matters
Subscribe to get the best content related to GvHD delivered to your inbox